230 related articles for article (PubMed ID: 30040280)
1. [Novel treatment options must prove their effectiveness: targeted treatment and immunotherapy for locally advanced melanoma].
van Thienen JV
Ned Tijdschr Geneeskd; 2018 Jun; 162():. PubMed ID: 30040280
[TBL] [Abstract][Full Text] [Related]
2. [Melanoma update].
Longvert C; Saiag P
Rev Med Interne; 2019 Mar; 40(3):178-183. PubMed ID: 30527396
[TBL] [Abstract][Full Text] [Related]
3. Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
Olszanski AJ
J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in malignant melanoma.
Atkinson V
Intern Med J; 2017 Oct; 47(10):1114-1121. PubMed ID: 28994264
[TBL] [Abstract][Full Text] [Related]
5. Melanoma treatment's changing landscape.
Jenks S
J Natl Cancer Inst; 2014 Jun; 106(6):dju176. PubMed ID: 24907389
[No Abstract] [Full Text] [Related]
6. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
8. Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.
Sinnamon AJ; Neuwirth MG; Gimotty PA; Gangadhar TC; Amaravadi RK; Schuchter LM; Karakousis GC
JAMA Oncol; 2018 Jan; 4(1):126-128. PubMed ID: 29145547
[TBL] [Abstract][Full Text] [Related]
9. [Study and treatment of locally advanced melanoma].
Moreno-Ramírez D; de la Cruz L; Ferrándiz L; Camacho FM
Actas Dermosifiliogr; 2009 Nov; 100(9):767-79. PubMed ID: 19889298
[TBL] [Abstract][Full Text] [Related]
10. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
[TBL] [Abstract][Full Text] [Related]
11. Current management of advanced melanoma: a transformed landscape.
Gyorki DE; Spillane J; Speakman D; Shackleton M; Henderson MA
ANZ J Surg; 2014 Sep; 84(9):612-7. PubMed ID: 24842394
[TBL] [Abstract][Full Text] [Related]
12. The role of targeted therapy for melanoma in the immunotherapy era.
Sullivan RJ
Semin Cutan Med Surg; 2018 Jun; 37(2):112-119. PubMed ID: 30040088
[TBL] [Abstract][Full Text] [Related]
13. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.
Eggermont AM
Eur J Cancer; 2016 Dec; 69():39-42. PubMed ID: 27816830
[TBL] [Abstract][Full Text] [Related]
15. Many ways to resistance: How melanoma cells evade targeted therapies.
Kozar I; Margue C; Rothengatter S; Haan C; Kreis S
Biochim Biophys Acta Rev Cancer; 2019 Apr; 1871(2):313-322. PubMed ID: 30776401
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
17. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
18. Side effects and toxicities of targeted therapies in stage IV melanoma.
Ascierto PA; Bastholt L; Hersey P; Cinat G; Eggermont AM; Hauschild A; Espinosa E; Robert C
Am J Ther; 2015; 22(1):44-53. PubMed ID: 24185314
[TBL] [Abstract][Full Text] [Related]
19. Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
Dummer R; Schadendorf D; Ascierto PA; Larkin J; Lebbé C; Hauschild A
Melanoma Res; 2015 Dec; 25(6):461-9. PubMed ID: 26426764
[TBL] [Abstract][Full Text] [Related]
20. Recent advancements in melanoma management.
Krishnan T; Menzies AM; Roberts-Thomson R
Intern Med J; 2021 Mar; 51(3):327-333. PubMed ID: 33738950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]